The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Press Releases

31. August 2021

Regulatory

Biosergen publishes interim report for the second quarter 2021

Download Press Release
24. August 2021

Non-Regulatory

Biosergen’s application to start human clinical trials with BSG005 is approved

Download Press Release
19. August 2021

Non-Regulatory

Tine Kold Olesen will join Biosergen AB as Chief Operating Officer

Download Press Release
27. Juni 2021

Regulatory

Biosergen’s groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the United States

Download Press Release
23. Juni 2021

Non-Regulatory

BIOSERGEN HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM.

Download Press Release
08. Juni 2021

Regulatory

BIOSERGEN’S OFFERING IS FULLY SUBSCRIBED

Download Press Release
31. Mai 2021

Non-Regulatory

The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity

Download Press Release
19. Mai 2021

Non-Regulatory

BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM

Download Press Release

Non-Regulatory

BIOSERGEN AVSER ATT NOTERA SINA AKTIER PÅ NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM

Download Press Release